Targeting the PI3K pathway for cancer therapy

Future Medicinal Chemistry

Volumn 4, Issue 9, 2012, Pages 1153-1169

  Sadeghi, Navid ^a   Gerber, David E ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 (2 DIFLUOROMETHYLBENZIMIDAZOL 1 YL) 4,6 DIMORPHOLINO 1,3,5 TRIAZINE; 2 MORPHOLINO 8 PHENYLCHROMONE; 5 FLUORO 3 PHENYL 2 [1 (9H PURIN 6 YLAMINO)PROPYL] 3H QUINAZOLIN 4 ONE; [1 (4 OXO 8 PHENYL 4H 1 BENZOPYRAN 2 YL)MORPHOLINIO]METHOXYSUCCINYLARGINYLGLYCYLASPARTYLSERINE ACETATE; AMG 319; ANTINEOPLASTIC AGENT; BENDAMUSTINE; BGT 226; BUPARLISIB; BYL 719; ERLOTINIB; EVEROLIMUS; FKBP 12; INK 1117; IRINOTECAN; LAPATINIB; LETROZOLE; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PF 04691502; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PKI 587; PLATINUM; RAPAMYCIN; RIDAFOROLIMUS; RITUXIMAB; TEMSIROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN INHIBITOR;

ABDOMINAL PAIN; ADVANCED CANCER; ANGIOGENESIS; ANOREXIA; ANXIETY; ASTHENIA; BREAST CANCER; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER PROGNOSIS; CANCER THERAPY; CELL GROWTH; CELL METABOLISM; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; COLON CANCER; COUGHING; CYTOPENIA; DEPRESSION; DIARRHEA; DRUG ERUPTION; DRUG SAFETY; DRUG TARGETING; ENDOMETRIUM CANCER; ENZYME ACTIVATION; FATIGUE; FEBRILE NEUTROPENIA; GENE AMPLIFICATION; GENE MUTATION; HUMAN; HYPERGLYCEMIA; HYPERTRANSAMINASEMIA; INFECTION; KIDNEY CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHOMA; MELANOMA; METASTASIS; MOOD CHANGE; MUCOSA INFLAMMATION; NAUSEA; NEUROENDOCRINE TUMOR; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PNEUMONIA; PRIORITY JOURNAL; REVIEW; SARCOMA; SIDE EFFECT; SIGNAL TRANSDUCTION; SOLID TUMOR; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; VOMITING;

ANTINEOPLASTIC AGENTS; CATALYTIC DOMAIN; ENZYME ACTIVATION; HUMANS; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84862557428     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.12.56     Document Type: Review

References (193)

1. Sugimoto Y, Whitman M, Cantley LC, Erikson RL. Evidence that the Rous sarcoma virus transforming gene product phosphorylates phosphatidylinositol and diacylglycerol. Proc. Natl Acad. Sci. USA 81(7), 2117-2121 (1984). (Pubitemid 14146614)
2. Whitman M, Kaplan D, Roberts T, Cantley L. Evidence for two distinct phosphatidylinositol kinases in fibroblasts. Implications for cellular regulation. Biochem. J. 247(1), 165-174 (1987).
3. Whitman M, Downes CP, Keeler M, Keller T, Cantley L. Type I phosphatidylinositol kinase makes a novel inositol phospholipid, phosphatidylinositol-3-phosphate. Nature 332(6165), 644-646 (1988).
4. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet. 7(8), 606-619 (2006). (Pubitemid 44100518)
5. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev. Cancer 2(7), 489-501 (2002). (Pubitemid 37328931)
6. Vanhaesebroeck B, Leevers SJ, Panayotou G, Waterfield MD. Phosphoinositide 3-kinases: a conserved family of signal transducers. Trends Biochem. Sci. 22(7), 267-272 (1997). (Pubitemid 27310948)
7. Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B. The emerging mechanisms of isoform-specific PI3K signalling. Nat. Rev. Mol. Cell Biol. 11(5), 329-341 (2010).
8. Fransson S, Uv A, Eriksson H et al. p37delta is a new isoform of PI3K p110delta that increases cell proliferation and is overexpressed in tumors. Oncogene doi:10.1038/onc.492 (2011) (Epub ahead of print).
9. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene 27(41), 5497-5510 (2008).
10. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat. Rev. Cancer 9(8), 550-562 (2009).
11. Kok K, Geering B, Vanhaesebroeck B. Regulation of phosphoinositide 3-kinase expression in health and disease. Trends Biochem. Sci. 34(3), 115-127 (2009).
12. Vanhaesebroeck B, Welham MJ, Kotani K et al. P110delta, a novel phosphoinositide 3-kinase in leukocytes. Proc. Natl Acad. Sci. USA 94(9), 4330-4335 (1997). (Pubitemid 27194241)
13. Voigt P, Dorner MB, Schaefer M. Characterization of p87PIKAP, a novel regulatory subunit of phosphoinositide 3-kinase g that is highly expressed in heart and interacts with PDE3B. J. Biol. Chem. 281(15), 9977-9986 (2006). (Pubitemid 43864530)
14. Kurig B, Shymanets A, Bohnacker T et al. Ras is an indispensable coregulator of the class IB phosphoinositide 3-kinase p87/p110g. Proc. Natl Acad. Sci. USA 106(48), 20312-20317 (2009).
15. Katso R, Okkenhaug K, Ahmadi K, White S, Timms J, Waterfield MD. Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu. Rev. Cell Dev. Biol. 17, 615-675 (2001). (Pubitemid 33096187)
16. Odorizzi G, Babst M, Emr SD. Phosphoinositide signaling and the regulation of membrane trafficking in yeast. Trends Biochem. Sci. 25(5), 229-235 (2000). (Pubitemid 30236220)
17. Yan Y, Flinn RJ, Wu H, Schnur RS, Backer JM. hVps15, but not Ca2+/CaM, is required for the activity and regulation of hVps34 in mammalian cells. Biochem. J. 417(3), 747-755 (2009).
18. Schu PV, Takegawa K, Fry MJ, Stack JH, Waterfield MD, Emr SD. Phosphatidylinositol 3-kinase encoded by yeast VPS34 gene essential for protein sorting. Science 260(5104), 88-91 (1993). (Pubitemid 23122750)
19. Vieira OV, Botelho RJ, Rameh L et al. Distinct roles of class I and class III phosphatidylinositol 3-kinases in phagosome formation and maturation. J. Cell Biol. 155(1), 19-25 (2001). (Pubitemid 34286204)
20. Nobukuni T, Joaquin M, Roccio M et al. Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase. Proc. Natl Acad. Sci. USA 102(40), 14238-14243 (2005). (Pubitemid 41429682)
21. Byfield MP, Murray JT, Backer JM. hVps34 is a nutrient-regulated lipid kinase required for activation of p70 S6 kinase. J. Biol. Chem. 280(38), 33076-33082 (2005). (Pubitemid 41368357)
22. Kihara A, Noda T, Ishihara N, Ohsumi Y. Two distinct Vps34 phosphatidylinositol 3-kinase complexes function in autophagy and carboxypeptidase Y sorting in Saccharomyces cerevisiae. J. Cell Biol. 152(3), 519-530 (2001). (Pubitemid 34280235)
23. Simonsen A, Tooze SA. Coordination of membrane events during autophagy by multiple class III PI3-kinase complexes. J. Cell. Biol. 186(6), 773-782 (2009).
24. Vanhaesebroeck B, Ali K, Bilancio A, Geering B, Foukas LC. Signalling by PI3K isoforms: insights from gene-targeted mice. Trends Biochem. Sci. 30(4), 194-204 (2005). (Pubitemid 40463309)
25. Gupta S, Ramjaun AR, Haiko P et al. Binding of ras to phosphoinositide 3-kinase p110a is required for ras-driven tumorigenesis in mice. Cell 129(5), 957-968 (2007). (Pubitemid 46802703)
26. Suire S, Condliffe AM, Ferguson GJ et al. Gb gs and the Ras binding domain of p110g are both important regulators of PI(3)K g signalling in neutrophils. Nat. Cell Biol. 8(11), 1303-1309 (2006). (Pubitemid 44660597)
27. Rodriguez-Viciana P, Sabatier C, Mccormick F. Signaling specificity by Ras family GTPases is determined by the full spectrum of effectors they regulate. Mol. Cell. Biol. 24(11), 4943-4954 (2004). (Pubitemid 38668058)
28. Delgado P, Cubelos B, Calleja E et al. Essential function for the GTPase TC21 in homeostatic antigen receptor signaling. Nat. Immunol. 10(8), 880-888 (2009).
29. Marques M, Kumar A, Cortes I et al. Phosphoinositide 3-kinases p110 a and p110 b regulate cell cycle entry, exhibiting distinct activation kinetics in G1 phase. Mol. Cell. Biol. 28(8), 2803-2814 (2008). (Pubitemid 351542377)
30. Kang S, Denley A, Vanhaesebroeck B, Vogt PK. Oncogenic transformation induced by the p110-b,-g, and-delta isoforms of class I phosphoinositide 3-kinase. Proc. Natl Acad. Sci. USA 103(5), 1289-1294 (2006). (Pubitemid 43191158)
31. Jimenez C, Hernandez C, Pimentel B, Carrera AC. The p85 regulatory subunit controls sequential activation of phosphoinositide 3-kinase by Tyr kinases and Ras. J. Biol. Chem. 277(44), 41556-41562 (2002). (Pubitemid 35257459)
32. Stoyanov B, Volinia S, Hanck T et al. Cloning and characterization of a G protein-activated human phosphoinositide-3 kinase. Science 269(5224), 690-693 (1995).
33. Guillermet-Guibert J, Bjorklof K, Salpekar A et al. The p110 b isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110g. Proc. Natl Acad. Sci. USA 105(24), 8292-8297 (2008). (Pubitemid 351904749)
34. Shin HW, Hayashi M, Christoforidis S et al. An enzymatic cascade of Rab5 effectors regulates phosphoinositide turnover in the endocytic pathway. J. Cell Biol. 170(4), 607-618 (2005). (Pubitemid 41186935)
35. Kurosu H, Maehama T, Okada T et al. Heterodimeric phosphoinositide 3-kinase consisting of p85 and p110b is synergistically activated by the bg subunits of G proteins and phosphotyrosyl peptide. J. Biol. Chem. 272(39), 24252-24256 (1997). (Pubitemid 27418626)
36. Christoforidis S, Miaczynska M, Ashman K et al. Phosphatidylinositol-3-OH kinases are Rab5 effectors. Nat. Cell Biol. 1(4), 249-252 (1999). (Pubitemid 129500945)
37. Bunney TD, Katan M. Phosphoinositide signalling in cancer: beyond PI3K and PTEN. Nat. Rev. Cancer. 10(5), 342-352 (2010).
38. Agoulnik IU, Hodgson MC, Bowden WA, Ittmann MM. INPP4B: the new kid on the PI3K block. Oncotarget 2(4), 321-328 (2011).
39. Fedele CG, Ooms LM, Ho M et al. Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers. Proc. Natl Acad. Sci. USA 107(51), 22231-22236 (2010).
40. Gewinner C, Wang ZC, Richardson A et al. Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell 16(2), 115-125 (2009).
41. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307(5712), 1098-1101 (2005). (Pubitemid 40262113)
42. Hooshmand-Rad R, Hajkova L, Klint P et al. The PI 3-kinase isoforms p110(a) and p110(b) have differential roles in PDGF-and insulin-mediated signaling. J. Cell Sci. 113(2) 207-214 (2000). (Pubitemid 30088966)
43. Roche S, Downward J, Raynal P, Courtneidge SA. A function for phosphatidylinositol 3-kinase b (p85a-p110b) in fibroblasts during mitogenesis: requirement for insulin-and lysophosphatidic acid-mediated signal transduction. Mol. Cell. Biol. 18(12), 7119-7129 (1998). (Pubitemid 28533031)
44. Siddhanta U, McIlroy J, Shah A, Zhang Y, Backer JM. Distinct roles for the p110a and hVPS34 phosphatidylinositol 3'-kinases in vesicular trafficking, regulation of the actin cytoskeleton, and mitogenesis. J. Cell Biol. 143(6), 1647-1659 (1998). (Pubitemid 29006509)
45. Vanhaesebroeck B, Jones GE, Allen WE et al. Distinct PI(3)Ks mediate mitogenic signalling and cell migration in macrophages. Nat. Cell Biol. 1(1), 69-71 (1999). (Pubitemid 129495013)
46. Foukas LC, Claret M, Pearce W et al. Critical role for the p110a phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature 441(7091), 366-370 (2006). (Pubitemid 44050203)
47. Bi L, Okabe I, Bernard DJ, Wynshaw-Boris A, Nussbaum RL. Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110a subunit of phosphoinositide 3-kinase. J. Biol. Chem. 274(16), 10963-10968 (1999).
48. Bi L, Okabe I, Bernard DJ, Nussbaum RL. Early embryonic lethality in mice deficient in the p110b catalytic subunit of PI 3-kinase. Mamm. Genome 13(3), 169-172 (2002). (Pubitemid 34185317)
49. Okkenhaug K, Bilancio A, Farjot G et al. Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science 297(5583), 1031-1034 (2002). (Pubitemid 34856039)
50. Ali K, Bilancio A, Thomas M et al. Essential role for the p110delta phosphoinositide 3-kinase in the allergic response. Nature 431(7011), 1007-1011 (2004). (Pubitemid 39434424)
51. Hirsch E, Katanaev VL, Garlanda C et al. Central role for G protein-coupled phosphoinositide 3-kinase g in inflammation. Science 287(5455), 1049-1053 (2000).
52. Sasaki T, Irie-Sasaki J, Jones RG et al. Function of PI3Kg in thymocyte development, T cell activation, and neutrophil migration. Science 287(5455), 1040-1046 (2000).
53. Inukai K, Funaki M, Anai M et al. Five isoforms of the phosphatidylinositol 3-kinase regulatory subunit exhibit different associations with receptor tyrosine kinases and their tyrosine phosphorylations. FEBS Lett. 490(1-2), 32-38 (2001). (Pubitemid 32126639)
54. Foukas LC, Berenjeno IM, Gray A, Khwaja A, Vanhaesebroeck B. Activity of any class IA PI3K isoform can sustain cell proliferation and survival. Proc. Natl Acad. Sci. USA 107(25), 11381-11386 (2010).
55. Hill KM, Kalifa S, Das JR et al. The role of PI 3-kinase p110b in AKT signally, cell survival, and proliferation in human prostate cancer cells. Prostate 70(7), 755-764 (2010).
56. Benistant C, Chapuis H, Roche S. A specific function for phosphatidylinositol 3-kinase a (p85a-p110a) in cell survival and for phosphatidylinositol 3-kinase b (p85a-p110b) in de novo DNA synthesis of human colon carcinoma cells. Oncogene 19(44), 5083-5090 (2000).
57. Hickey FB, Cotter TG. BCR-ABL regulates phosphatidylinositol 3-kinase-p110g transcription and activation and is required for proliferation and drug resistance. J. Biol. Chem. 281(5), 2441-2450 (2006). (Pubitemid 43845703)
58. Sujobert P, Bardet V, Cornillet-Lefebvre P et al. Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood 106(3), 1063-1066 (2005). (Pubitemid 41076455)
59. Vasudevan KM, Barbie DA, Davies MA et al. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell 16(1), 21-32 (2009).
60. Inoki K, Li Y, Xu T, Guan KL. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev. 17(15), 1829-1834 (2003). (Pubitemid 36944560)
61. Tee AR, Fingar DC, Manning BD, Kwiatkowski DJ, Cantley LC, Blenis J. Tuberous sclerosis complex-1 and-2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc. Natl Acad. Sci. USA 99(21), 13571-13576 (2002). (Pubitemid 35215423)
62. Fingar DC, Salama S, Tsou C, Harlow E, Blenis J. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev. 16(12), 1472-1487 (2002). (Pubitemid 34686329)
63. O'Reilly KE, Rojo F, She QB et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 66(3), 1500-1508 (2006). (Pubitemid 43259931)
64. Manning BD. Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis. J. Cell Biol. 167(3), 399-403 (2004). (Pubitemid 39489047)
65. Thong FS, Dugani CB, Klip A. Turning signals on and off: GLUT4 traffic in the insulin-signaling highway. Physiology (Bethesda) 20(4), 271-284 (2005). (Pubitemid 41215201)
66. Luo J, Sobkiw CL, Hirshman MF et al. Loss of class IA PI3K signaling in muscle leads to impaired muscle growth, insulin response, and hyperlipidemia. Cell Metab. 3(5), 355-366 (2006).
67. Cho H, Mu J, Kim JK et al. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB b). Science 292(5522), 1728-1731 (2001). (Pubitemid 32506248)
68. Brunet A, Bonni A, Zigmond MJ et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96(6), 857-868 (1999). (Pubitemid 29165088)
69. Duronio V. The life of a cell: apoptosis regulation by the PI3K/PKB pathway. Biochem. J. 415(3), 333-344 (2008).
70. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB. NF-kB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 401(6748), 82-85 (1999).
71. Mayo LD, Dixon JE, Durden DL, Tonks NK, Donner DB. PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. J. Biol. Chem. 277(7), 5484-5489 (2002). (Pubitemid 34968598)
72. Mayo LD, Donner DB. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc. Natl Acad. Sci. USA 98(20), 11598-11603 (2001). (Pubitemid 32928774)
73. Zhou BP, Liao Y, Xia W, Zou Y, Spohn B, Hung MC. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat. Cell Biol. 3(11), 973-982 (2001). (Pubitemid 34428742)
74. Gardai SJ, Hildeman DA, Frankel SK et al. Phosphorylation of Bax Ser184 by Akt regulates its activity and apoptosis in neutrophils. J. Biol. Chem. 279(20), 21085-21095 (2004). (Pubitemid 38656511)
75. Datta SR, Dudek H, Tao X et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91(2), 231-241 (1997). (Pubitemid 27456390)
76. Del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 278(5338), 687-689 (1997). (Pubitemid 27464966)
77. Ekert PG, Jabbour AM, Manoharan A et al. Cell death provoked by loss of interleukin-3 signaling is independent of Bad, Bim, and PI3 kinase, but depends in part on Puma. Blood 108(5), 1461-1468 (2006). (Pubitemid 44316109)
78. Hinton HJ, Welham MJ. Cytokine-induced protein kinase B activation and Bad phosphorylation do not correlate with cell survival of hemopoietic cells. J. Immunol. 162(12), 7002-7009 (1999). (Pubitemid 29277666)
79. Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase-3b regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 12(22), 3499-3511 (1998). (Pubitemid 28553242)
80. Mirza AM, Gysin S, Malek N, Nakayama K, Roberts JM, McMahon M. Cooperative regulation of the cell division cycle by the protein kinases RAF and AKT. Mol. Cell. Biol. 24(24), 10868-10881 (2004). (Pubitemid 39603142)
81. Medema RH, Kops GJ, Bos JL, Burgering BM. AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature 404(6779), 782-787 (2000). (Pubitemid 30212408)
82. Jiang BH, Zheng JZ, Aoki M, Vogt PK. Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. Proc. Natl Acad. Sci. USA 97(4), 1749-1753 (2000). (Pubitemid 30118514)
83. Graupera M, Guillermet-Guibert J, Foukas LC et al. Angiogenesis selectively requires the p110a isoform of PI3K to control endothelial cell migration. Nature 453(7195), 662-666 (2008). (Pubitemid 351769296)
84. Forsythe JA, Jiang BH, Iyer NV et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol. 16(9), 4604-4613 (1996). (Pubitemid 26272112)
85. Zhong H, Chiles K, Feldser D et al. Modulation of hypoxia-inducible factor 1a expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res. 60(6), 1541-1545 (2000). (Pubitemid 30183422)
86. Choi SB, Park JB, Song TJ, Choi SY. Molecular mechanism of HIF-1-independent VEGF expression in a hepatocellular carcinoma cell line. Int. J. Mol. Med. 28(3), 449-454 (2011).
87. Defatta RJ, Nathan CO, De Benedetti A. Antisense RNA to eIF4E suppresses oncogenic properties of a head and neck squamous cell carcinoma cell line. Laryngoscope 110(6), 928-933 (2000). (Pubitemid 30368633)
88. Brugarolas JB, Vazquez F, Reddy A, Sellers WR, Kaelin WG Jr. TSC2 regulates VEGF through mTOR-dependent and-independent pathways. Cancer Cell 4(2), 147-158 (2003). (Pubitemid 37045363)
89. Babaei S, Teichert-Kuliszewska K, Zhang Q, Jones N, Dumont DJ, Stewart DJ. Angiogenic actions of angiopoietin-1 require endothelium-derived nitric oxide. Am. J. Pathol 162(6), 1927-1936 (2003). (Pubitemid 36613050)
90. Kim D, Kim S, Koh H et al. Akt/PKB promotes cancer cell invasion via increased motility and metalloproteinase production. FASEB J. 15(11), 1953-1962 (2001). (Pubitemid 32848799)
91. Shukla S, Maclennan GT, Hartman DJ, Fu P, Resnick MI, Gupta S. Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion. Int. J. Cancer 121(7), 1424-1432 (2007). (Pubitemid 47328700)
92. Chen JS, Wang Q, Fu XH et al. Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: Association with MMP-9. Hepatol. Res. 39(2), 177-186 (2009).
93. Gulhati P, Bowen KA, Liu J et al. mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways. Cancer Res. 71(9), 3246-3256 (2011).
94. Tkach V, Bock E, Berezin V. The role of RhoA in the regulation of cell morphology and motility. Cell Motil. Cytoskeleton 61(1), 21-33 (2005). (Pubitemid 40604948)
95. Jaffe AB, Hall A. Rho GTPases in transformation and metastasis. Adv. Cancer Res. 84, 57-80 (2002). (Pubitemid 34188194)
96. Knowles JA, Golden B, Yan L, Carroll WR, Helman EE, Rosenthal EL. Disruption of the AKT pathway inhibits metastasis in an orthotopic model of head and neck squamous cell carcinoma. Laryngoscope 121(11), 2359-2365 (2011).
97. Shigematsu H, Lin L, Takahashi T et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J. Natl Cancer Inst. 97(5), 339-346 (2005). (Pubitemid 40425952)
98. Samuels Y, Velculescu VE. Oncogenic mutations of PIK3CA in human cancers. Cell Cycle 3(10), 1221-1224 (2004). (Pubitemid 40268595)
99. Vogt PK, Kang S, Elsliger MA, Gymnopoulos M. Cancer-specific mutations in phosphatidylinositol 3-kinase. Trends Biochem. Sci. 32(7), 342-349 (2007). (Pubitemid 47021415)
100. Bader AG, Kang S, Zhao L, Vogt PK. Oncogenic PI3K deregulates transcription and translation. Nat. Rev. Cancer 5(12), 921-929 (2005). (Pubitemid 41766781)
101. Zhao L, Vogt PK. Class I PI3K in oncogenic cellular transformation. Oncogene 27(41), 5486-5496 (2008).
102. Okudela K, Suzuki M, Kageyama S et al. PIK3CA mutation and amplification in human lung cancer. Pathol. Int. 57(10), 664-671 (2007). (Pubitemid 47353042)
103. Garcia JM, Silva J, Pena C et al. Promoter methylation of the PTEN gene is a common molecular change in breast cancer. Genes Chromosomes Cancer 41(2), 117-124 (2004). (Pubitemid 39096737)
104. Carracedo A, Pandolfi PP. The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene 27(41), 5527-5541 (2008).
105. Cornejo MG, Mabialah V, Sykes SM et al. Crosstalk between NOTCH and AKT signaling during murine megakaryocyte lineage specification. Blood 118(5), 1264-1273 (2011).
106. Moreno CS. The Sex-determining region Y-box 4 and homeobox C6 transcriptional networks in prostate cancer progression: crosstalk with the Wnt, Notch, and PI3K pathways. Am. J. Pathol. 176(2), 518-527 (2010).
107. Byun JY, Kim MJ, Yoon CH, Cha H, Yoon G, Lee SJ. Oncogenic Ras signals through activation of both phosphoinositide 3-kinase and Rac1 to induce c-Jun NH2-terminal kinase-mediated, caspase-independent cell death. Mol. Cancer Res. 7(9), 1534-1542 (2009)
108. Ma L, Chen Z, Erdjument-Bromage H, Tempst P, Pandolfi PP. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 121(2), 179-193 (2005). (Pubitemid 40546387)
109. Massarweh S, Schiff R. Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities. Clin. Cancer Res. 13(7), 1950-1954 (2007). (Pubitemid 46649859)
110. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor a: a new model for anti-estrogen resistance. J. Biol. Chem. 276(13), 9817-9824 (2001).
111. Beeram M, Tan QT, Tekmal RR, Russell D, Middleton A, Degraffenried LA. Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling. Ann. Oncol. 18(8), 1323-1328 (2007). (Pubitemid 47305004)
112. Degraffenried LA, Friedrichs WE, Russell DH et al. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. Clin. Cancer Res. 10(23), 8059-8067 (2004). (Pubitemid 39587547)
113. Baselga J, Semiglazov V, Van Dam P et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J. Clin. Oncol. 27(16), 2630-2637 (2009).
114. Berns K, Horlings HM, Hennessy BT et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12(4), 395-402 (2007). (Pubitemid 47539306)
115. Nagata Y, Lan KH, Zhou X et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6(2), 117-127 (2004). (Pubitemid 39485684)
116. Eichhorn PJ, Gili M, Scaltriti M et al. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res. 68(22), 9221-9230 (2008).
117. Dave B, Migliaccio I, Gutierrez MC et al. Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers. J. Clin. Oncol. 29(2), 166-173 (2011).
118. Wang L, Zhang Q, Zhang J et al. PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib. BMC Cancer doi:10.1186/1471-2407-11- 248 (2011).
119. Li SY, Rong M, Grieu F, Iacopetta B. PIK3CA mutations in breast cancer are associated with poor outcome. Breast Cancer Res. Treat. 96(1), 91-95 (2006).
120. Capodanno A, Camerini A, Orlandini C et al. Dysregulated PI3K/Akt/PTEN pathway is a marker of a short disease-free survival in node-negative breast carcinoma. Hum. Pathol. 40(10), 1408-1417 (2009).
121. Woenckhaus J, Steger K, Sturm K, Munstedt K, Franke FE, Fenic I. Prognostic value of PIK3CA and phosphorylated AKT expression in ovarian cancer. Virchows Arch. 450(4), 387-395 (2007). (Pubitemid 46466383)
122. Kolasa IK, Rembiszewska A, Felisiak A et al. PIK3CA amplification associates with resistance to chemotherapy in ovarian cancer patients. Cancer Biol. Ther. 8(1), 21-26 (2009).
123. Salvesen HB, Carter SL, Mannelqvist M et al. Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proc. Natl Acad. Sci. USA 106(12), 4834-4839 (2009).
124. Farina Sarasqueta A, Zeestraten EC, Van Wezel T et al. PIK3CA kinase domain mutation identifies a subgroup of stage III colon cancer patients with poor prognosis. Cell. Oncol. (Dordr.) 34(6), 523-531 (2011).
125. Ludovini V, Bianconi F, Pistola L et al. Phosphoinositide-3-kinase catalytic a and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer. J. Thorac. Oncol. 6(4), 707-715 (2011).
126. Sos ML, Koker M, Weir BA et al. PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res. 69(8), 3256-3261 (2009).
127. Pu X, Hildebrandt MA, Lu C et al. PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy. Lung Cancer 71(1), 82-88 (2011).
128. Hirami Y, Aoe M, Tsukuda K et al. Relation of epidermal growth factor receptor, phosphorylated-Akt, and hypoxia-inducible factor-1a in non-small cell lung cancers. Cancer Lett. 214(2), 157-164 (2004). (Pubitemid 39207976)
129. Schuurbiers OC, Kaanders JH, Van Der Heijden HF, Dekhuijzen RP, Oyen WJ, Bussink J. The PI3-K/AKT-pathway and radiation resistance mechanisms in non-small cell lung cancer. J. Thorac. Oncol. 4(6), 761-767 (2009).
130. Grana B, Burris HA, Rodon Ahnert J et al. Oral PI3 kinase inhibitor BKM120 monotherapy in patients (pts) with advanced solid tumors: an update on safety and efficacy. J. Clin. Oncol. 29 (SUPPL. Abstract 3043) (2011).
131. Coutre SE, Byrd JC, Furman RR et al. Phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110d, in patients with previously treated chronic lymphocytic leukemia. J. Clin. Oncol. 29(SUPPL. Abstr. 6631) (2011).
132. Flinn IW, Schreeder MT, Coutre SE et al. A Phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110d, in combination with anti-CD20 monoclonal antibody therapy and/or bendamustine in patients with previously treated B-cell malignancies. J. Clin. Oncol. 29(SUPPL. Abstr. 3064) (2011).
133. Brunn GJ, Williams J, Sabers C, Wiederrecht G, Lawrence JC Jr, Abraham RT. Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002. EMBO J. 15(19), 5256-5267 (1996). (Pubitemid 26336209)
134. Peyton JD, Rodon Ahnert J, Burris H et al. A dose-escalation study with the novel formulation of the oral pan-class I PI3K inhibitor BEZ235, solid dispersion system (SDS) sachet, in patients with advanced solid tumors. J. Clin. Oncol. 29 (SUPPL. Abstr. 3066) (2011).
135. Abraham RT, Gibbons JJ. The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy. Clin. Cancer Res. 13(11), 3109-3114 (2007). (Pubitemid 46944891)
136. Sarbassov DD, Ali SM, Kim DH et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol. 14(14), 1296-1302 (2004). (Pubitemid 38991819)
137. Jacinto E, Loewith R, Schmidt A et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat. Cell Biol. 6(11), 1122-1128 (2004). (Pubitemid 39468014)
138. Dancey JE, Monzon J. Ridaforolimus: a promising drug in the treatment of soft-tissue sarcoma and other malignancies. Future Oncol. 7(7), 827-839 (2011).
139. Chawla SP, Blay J, Ray-Coquard IL et al. Results of the Phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT). J. Clin. Oncol. 29 (SUPPL. Abstr. 10005) (2011).
140. Tan DS, Dumez H, Olmos D et al. First-in-human Phase I study exploring three schedules of OSI-027, a novel small molecule TORC1/TORC2 inhibitor, in patients with advanced solid tumors and lymphoma. J. Clin. Oncol. 28(15s), (SUPPL. Abstr. 3006) (2010)
141. Cheng JQ, Lindsley CW, Cheng GZ, Yang H, Nicosia SV. The Akt/PKB pathway: molecular target for cancer drug discovery. Oncogene 24(50), 7482-7492 (2005). (Pubitemid 41637988)
142. Yap TA, Patnaik A, Fearen I et al. First-in-class Phase I trial of a selective Akt inhibitor, MK2206 (MK), evaluating alternate day (QOD) and once weekly (QW) doses in advanced cancer patients (pts) with evidence of target modulation and antitumor activity. J. Clin. Oncol. 28(SUPPL. Abstr. 15), 3009 (2010).
143. Inukai K, Funaki M, Ogihara T et al. p85a gene generates three isoforms of regulatory subunit for phosphatidylinositol 3-kinase (PI 3-Kinase), p50a, p55a, and p85a, with different PI 3-kinase activity elevating responses to insulin. J. Biol. Chem. 272(12), 7873-7882 (1997). (Pubitemid 27137347)
144. Inukai K, Anai M, Van Breda E et al. A novel 55-kDa regulatory subunit for phosphatidylinositol 3-kinase structurally similar to p55PIK Is generated by alternative splicing of the p85a gene. J. Biol. Chem. 271(10), 5317-5320 (1996).
145. Hu P, Mondino A, Skolnik EY, Schlessinger J. Cloning of a novel, ubiquitously expressed human phosphatidylinositol 3-kinase and identification of its binding site on p85. Mol. Cell. Biol. 13(12), 7677-7688 (1993). (Pubitemid 23354292)
146. Suire S, Coadwell J, Ferguson GJ, Davidson K, Hawkins P, Stephens L. p84, a new Gbg-activated regulatory subunit of the type IB phosphoinositide 3-kinase p110g. Curr. Biol. 15(6), 566-570 (2005). (Pubitemid 40413397)
147. Domin J, Pages F, Volinia S et al. Cloning of a human phosphoinositide 3-kinase with a C2 domain that displays reduced sensitivity to the inhibitor wortmannin. Biochem. J. 326(1), 139-147 (1997). (Pubitemid 27386928)
148. Brown RA, Ho LK, Weber-Hall SJ, Shipley JM, Fry MJ. Identification and cDNA cloning of a novel mammalian C2 domain-containing phosphoinositide 3-kinase, HsC2-PI3K. Biochem. Biophys. Res. Commun. 233(2), 537-544 (1997). (Pubitemid 27226663)
149. Rozycka M, Lu YJ, Brown RA, Lau MR, Shipley JM, Fry MJ. cDNA cloning of a third human C2-domain-containing class II phosphoinositide 3-kinase, PI3K-C2g, and chromosomal assignment of this gene (PIK3C2G) to 12p12. Genomics 54(3), 569-574 (1998). (Pubitemid 29036246)
150. Panaretou C, Domin J, Cockcroft S, Waterfield MD. Characterization of p150, an adaptor protein for the human phosphatidylinositol (PtdIns) 3-kinase. Substrate presentation by phosphatidylinositol transfer protein to the p150.Ptdins 3-kinase complex. J. Biol. Chem. 272(4), 2477-2485 (1997). (Pubitemid 27058539)
151. Volinia S, Dhand R, Vanhaesebroeck B et al. A human phosphatidylinositol 3-kinase complex related to the yeast Vps34p-Vps15p protein sorting system. EMBO J. 14(14), 3339-3348 (1995).
152. Wu G, Xing M, Mambo E et al. Somatic mutation and gain of copy number of PIK3CA in human breast cancer. Breast Cancer Res. 7(5), R609-616 (2005).
153. Levine DA, Bogomolniy F, Yee CJ et al. Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin. Cancer Res. 11(8), 2875-2878 (2005). (Pubitemid 40525186)
154. Bachman KE, Argani P, Samuels Y et al. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol. Ther. 3(8), 772-775 (2004). (Pubitemid 41351083)
155. Rudd ML, Price JC, Fogoros S et al. A unique spectrum of somatic PIK3CA (p110a) mutations within primary endometrial carcinomas. Clin. Cancer Res. 17(6), 1331-1340 (2011).
156. Broderick DK, Di C, Parrett TJ et al. Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Res. 64(15), 5048-5050 (2004). (Pubitemid 39006515)
157. Campbell IG, Russell SE, Choong DY et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 64(21), 7678-7681 (2004). (Pubitemid 39446895)
158. Pedrero JM, Carracedo DG, Pinto CM et al. Frequent genetic and biochemical alterations of the PI 3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma. Int. J. Cancer 114(2), 242-248 (2005). (Pubitemid 40194293)
159. Racz A, Brass N, Heckel D, Pahl S, Remberger K, Meese E. Expression analysis of genes at 3q26-q27 involved in frequent amplification in squamous cell lung carcinoma. Eur. J. Cancer 35(4), 641-646 (1999). (Pubitemid 29192975)
160. Ma YY, Wei SJ, Lin YC et al. PIK3CA as an oncogene in cervical cancer. Oncogene 19(23), 2739-2744 (2000).
161. Byun DS, Cho K, Ryu BK et al. Frequent monoallelic deletion of PTEN and its reciprocal associatioin with PIK3CA amplification in gastric carcinoma. Int. J. Cancer 104(3), 318-327 (2003). (Pubitemid 36249814)
162. Miller CT, Moy JR, Lin L et al. Gene amplification in esophageal adenocarcinomas and Barrett's with high-grade dysplasia. Clin. Cancer Res. 9(13), 4819-4825 (2003). (Pubitemid 37323285)
163. Wu G, Mambo E, Guo Z et al. Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors. J. Clin. Endocrinol. Metab. 90(8), 4688-4693 (2005). (Pubitemid 41159359)
164. Sun X, Huang J, Homma T et al. Genetic alterations in the PI3K pathway in prostate cancer. Anticancer Res. 29(5), 1739-1743 (2009).
165. Mizoguchi M, Nutt CL, Mohapatra G, Louis DN. Genetic alterations of phosphoinositide 3-kinase subunit genes in human glioblastomas. Brain Pathol. 14(4), 372-377 (2004). (Pubitemid 39524966)
166. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455(7216), 1061-1068 (2008).
167. Philp AJ, Campbell IG, Leet C et al. The phosphatidylinositol 3'-kinase p85a gene is an oncogene in human ovarian and colon tumors. Cancer Res. 61(20), 7426-7429 (2001). (Pubitemid 32995029)
168. Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW. PIK3R1 (p85a) is somatically mutated at high frequency in primary endometrial cancer. Cancer Res. 71(12), 4061-4067 (2011).
169. Liaw D, Marsh DJ, Li J et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat. Genet. 16(1), 64-67 (1997). (Pubitemid 27198157)
170. Tashiro H, Blazes MS, Wu R et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer. Res. 57(18), 3935-3940 (1997). (Pubitemid 27427679)
171. Li J, Yen C, Liaw D et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275(5308), 1943-1947 (1997). (Pubitemid 27148818)
172. Wiencke JK, Zheng S, Jelluma N et al. Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma. Neuro. Oncol. 9(3), 271-279 (2007). (Pubitemid 47169659)
173. Whang YE, Wu X, Suzuki H et al. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc. Natl Acad. Sci. USA 95(9), 5246-5250 (1998). (Pubitemid 28208583)
174. Mirmohammadsadegh A, Marini A, Nambiar S et al. Epigenetic silencing of the PTEN gene in melanoma. Cancer Res. 66(13), 6546-6552 (2006). (Pubitemid 44085609)
175. Lahtz C, Stranzenbach R, Fiedler E, Helmbold P, Dammann RH. Methylation of PTEN as a prognostic factor in malignant melanoma of the skin. J. Invest. Dermatol. 130(2), 620-622 (2010).
176. Kang YH, Lee HS, Kim WH. Promoter methylation and silencing of PTEN in gastric carcinoma. Lab. Invest. 82(3), 285-291 (2002).
177. Goel A, Arnold CN, Niedzwiecki D et al. Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers. Cancer Res. 64(9), 3014-3021 (2004). (Pubitemid 38581399)
178. Salvesen HB, Macdonald N, Ryan A et al. PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma. Int. J. Cancer 91(1), 22-26 (2001).
179. Soria JC, Lee HY, Lee JI et al. Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin. Cancer. Res. 8(5), 1178-1184 (2002). (Pubitemid 34517656)
180. Ohgaki H, Dessen P, Jourde B et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res. 64(19), 6892-6899 (2004). (Pubitemid 39330996)
181. Cairns P, Okami K, Halachmi S et al. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res. 57(22), 4997-5000 (1997). (Pubitemid 27498107)
182. Carpten JD, Faber AL, Horn C et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448(7152), 439-444 (2007). (Pubitemid 47123510)
183. Kim MS, Jeong EG, Yoo NJ, Lee SH. Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias. Br. J. Cancer 98(9), 1533-1535 (2008). (Pubitemid 351652321)
184. Malanga D, Scrima M, De Marco C et al. Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung. Cell Cycle 7(5), 665-669 (2008). (Pubitemid 351499006)
185. Shoji K, Oda K, Nakagawa S et al. The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas. Br. J. Cancer 101(1), 145-148 (2009).
186. Staal SP. Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proc. Natl Acad. Sci. USA 84(14), 5034-5037 (1987). (Pubitemid 17095859)
187. Parsons DW, Wang TL, Samuels Y et al. Colorectal cancer: mutations in a signalling pathway. Nature 436(7052), 792 (2005). (Pubitemid 41160630)
188. Cheng JQ, Ruggeri B, Klein WM et al. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc. Natl Acad. Sci. USA 93(8), 3636-3641 (1996). (Pubitemid 26127592)
189. Ruggeri BA, Huang L, Wood M, Cheng JQ, Testa JR. Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas. Mol. Carcinog. 21(2), 81-86 (1998). (Pubitemid 28122842)
190. Cheng JQ, Godwin AK, Bellacosa A et al. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc. Natl Acad. Sci. USA 89(19), 9267-9271 (1992).
191. Bellacosa A, De Feo D, Godwin AK et al. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int. J. Cancer 64(4), 280-285 (1995).
192. Arranz E, Robledo M, Martinez B et al. Incidence of homogeneously staining regions in non-Hodgkin lymphomas. Cancer Genet. Cytogenet. 87(1), 1-3 (1996). (Pubitemid 26113595)
193. Davies MA, Stemke-Hale K, Tellez C et al. A novel AKT3 mutation in melanoma tumours and cell lines. Br. J. Cancer 99(8), 1265-1268 (2008).